Kevin Weil, the former OpenAI executive who led the ChatGPT maker’s AI-for-science efforts, is launching a new startup with $215 million, Bloomberg reported on 22 October 2026. Bloomberg’s summary says the startup is aimed at using artificial intelligence to speed up a key step of drug development.
In August, Business Insider reported that Weil was aiming to raise $150 million at a valuation of at least $750 million, citing three people with knowledge of the discussions. By our arithmetic, $215 million is about 43% more than that August target. Bloomberg’s full report, carried by Investing.com, names the company Warp Sciences and says the funding values it at $865 million after the new money, in a round led by Lightspeed Venture Partners.
Update, 22 October 2026
Bloomberg’s full report, as carried by Investing.com, gives the details we did not have at first. The startup is Warp Sciences. Lightspeed Venture Partners led the $215 million round, with participation from IVP, Premji Invest and Lux Capital, and the funding values Warp at $865 million after the new money. Angel investors include OpenAI Chief Financial Officer Sarah Friar, Fidji Simo, Coinbase Chief Executive Brian Armstrong, Palantir Chief Technology Officer Shyam Sankar and LinkedIn co-founder Reid Hoffman. Weil is chief executive; his co-founders include Manohar Paluri, a former vice president at Meta’s Superintelligence Labs, DJ Patil, the White House’s first chief data scientist, and Solomon Reisberg, a former executive at Terremoto Biosciences. Bloomberg says the company is starting with about 20 people and is targeting a step of drug development that pharmaceutical companies have historically outsourced to Chinese firms such as WuXi AppTec. By our arithmetic, the $865 million valuation is about 15% above the “at least $750 million” Business Insider said Weil was seeking in August; because that August figure was a floor, the comparison is approximate.
Business Pill · DATA QUALITY
A one-minute explainer on why fewer, better training examples can matter more than volume. It teaches the general idea only and says nothing about any company in this piece.
The key insight: As we read it, the new figure is the size: Bloomberg reports $215 million at launch, about 43% more than the $150 million Business Insider’s sources said Weil was aiming to raise in August, by our arithmetic.
Update (23 Oct): Weil’s own announcement and TechCrunch’s details. In his post on X on 22 October, Weil described Warp Sciences as “a new company applying AI and robotics to help the world develop new medicines faster” and said the $215M Series A, led by Lightspeed, is meant “to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America.” He named his co-founders as DJ Patil, Manohar Paluri and Sol Reisberg, and said the early team includes @bkspears9, “who helped achieve Q>1 fusion at LLNL.”
TechCrunch reported that Mayfield and Menlo Ventures also took part in the round, alongside IVP, Lux Capital and Premji Invest. It reported that the startup’s human chemists, “wearing cameras and sensor gloves,” will train robots to perform lab tasks, with the aim of accelerating drug discovery “using robots that can operate around the clock,” and that Weil hopes to reshore work biotech companies have long outsourced to contractors in China such as WuXi AppTec.
As we read it, the comparison with WuXi AppTec suggests a contract-lab shape, with the chemists’ work doubling as training data for the robots; neither source sets out how Warp will charge.
The headline. “Ex-OpenAI Science Head Launches Startup With $215 Million”, published by Bloomberg on 22 October 2026 and posted on its X account at 15:35 UTC.
The summary. Bloomberg describes Weil as the former OpenAI executive “who led the ChatGPT maker’s AI-for-science efforts”, and says the new startup is aimed at using artificial intelligence “to speed up a key step” of drug development (the summary shown to us is cut off at that word).
The details (full report via Investing.com). The company is Warp Sciences. Lightspeed Venture Partners led the round, with IVP, Premji Invest and Lux Capital; the funding values Warp at $865 million after the new money. Weil is chief executive, and the company is starting with about 20 people. Bloomberg says it targets a step of drug development that pharmaceutical companies have historically outsourced to Chinese firms such as WuXi AppTec.
Business Insider reported in August, citing three people, that Weil was aiming to raise $150 million at a valuation of at least $750 million; Bloomberg reported on 22 October 2026 that he is launching a startup with $215 million. The 43% is our arithmetic across two outlets and dates; the August figure was a target.
Bloomberg posted its report on X at 15:35 UTC on 22 October 2026 under the line “Ex-OpenAI science head Kevin Weil launches startup with $215 million”. It is the report this piece is based on; we first read its headline and summary, then its full text as carried by Investing.com.
💥 Introducing Warp Sciences, a new company applying AI and robotics to help the world develop new medicines faster.
We’ve raised a $215M Series A led by @lightspeedvp to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America.
I co-founded Warp with my long-time friend @dpatil, FAIR co-founder @manohar_paluri, and drug hunter Sol Reisberg. The early team is full of incredible people like @bkspears9, who helped achieve Q>1 fusion at LLNL.
Kevin Weil announced Warp Sciences on X, describing it as a new company applying AI and robotics to help the world develop new medicines faster, and said it raised a $215M Series A led by Lightspeed.
What Business Insider Reported in August
Business Insider reported the fundraising on 11 August 2026, citing three people with knowledge of the discussions.
The target. Weil “has sought a valuation of at least $750 million” and was aiming to raise $150 million in the round. The details had not been finalised and could still change, the outlet said.
The pitch. The exact details of the startup could not be learned, Business Insider wrote, but sources said Weil had pitched it as a way to gather scientific data for AI models.
His record. Weil was OpenAI’s chief product officer and then oversaw its science initiatives, including Prism, a workspace for bringing frontier models into scientists’ workflows, according to Business Insider. Before OpenAI he was a product executive at Meta and Twitter, and he sits on boards including Cisco and Stoke Space.
No comment. Weil did not respond to a request for comment, the outlet said.
Item
Figure
Source
Fundraising target, as reported in August
$150 million, at a valuation of at least $750 million; details not finalised
Business Insider, citing three people with knowledge of the discussions
Launch amount, as reported in October
$215 million
Bloomberg
Difference
About 43% more than the August target
Our arithmetic
The August figures were a target reported from sources; the October figure is Bloomberg’s. Bloomberg’s full report describes the $215 million as a round led by Lightspeed Venture Partners.
The Arithmetic
About 43% above the August target. $215 million against $150 million is about 1.43 times, by our arithmetic. The two figures come from different outlets and dates, and the August one was a target.
At least $750 million in August. That was the floor Business Insider’s sources gave for the valuation Weil sought. Bloomberg’s full report puts the valuation at $865 million after the new money, about 15% above that floor by our arithmetic.
A Crowded AI-for-Science Field
Business Insider placed Weil’s plan in a wider move by OpenAI and Google alumni into startups that promise to speed up scientific discovery.
Periodic Labs. Founded by former OpenAI researcher Liam Fedus and former Google DeepMind researcher Ekin Dogus Cubuk, it is building AI scientists alongside autonomous laboratories, with investors including Andreessen Horowitz, Accel, Jeff Bezos and Eric Schmidt, according to Business Insider.
Discovery Loop.Google’s chief scientist Jeff Dean announced, in the week before Business Insider’s 11 August report, that he and three colleagues were leaving to start it, focused on AI applications in science and engineering, the outlet reported.
Other OpenAI moves. Business Insider cited other senior changes: Brad Lightcap announced he was leaving, Fidji Simo stepped down as CEO of applications and moved into a part-time advisory role, and Bill Peebles and Srinivas Narayanan left in April.
Connecting the Coverage
Our piece on OpenAI’s 722 math manuscripts covered the science work of the lab Weil left, including this week’s critique of that release on Terence Tao’s blog.
As we read it, the two reports describe one plan from two angles. Business Insider’s sources said Weil pitched a way to gather scientific data for AI models, and Bloomberg’s summary says the startup aims to use AI to speed up a key step of drug development.
As we read it, the founder’s record is the main asset on view. Business Insider says Weil was OpenAI’s chief product officer and then oversaw its science initiatives, including Prism.
As we read it, the field is filling with lab alumni. Business Insider names Periodic Labs, founded by a former OpenAI researcher and a former Google DeepMind researcher, and Jeff Dean’s Discovery Loop.
Business Insider, 11 August 2026
“Weil’s fundraising is the latest sign that AI’s next frontier is shifting from chatbots to science.”
Three Implications
FOR INVESTORS Business Insider reported in August that Weil sought a valuation of at least $750 million; Bloomberg’s full report, carried by Investing.com, gives $215 million at an $865 million valuation after the new money, in a round led by Lightspeed Venture Partners.
FOR AI LABS Business Insider reported that a growing number of OpenAI and Google alumni are launching startups that promise to accelerate scientific discovery.
FOR THE SCIENCE-DATA MARKET Business Insider’s sources said Weil pitched his startup as a way to gather scientific data for AI models.
The framework opens: “Every AI paradigm produces a different kind of moat. The transformer is a commodity now; what changes between paradigms is where intelligence accumulates and who can capture it.”
As we read it, a startup pitched as a way to gather scientific data for AI models, as Business Insider’s sources described Weil’s, is a bet on where that accumulation happens. The framework was published in July 2026 and does not discuss this company.
What Is Not Established
At first we could read only Bloomberg’s headline and summary; the full report, carried by Investing.com, later supplied the name, investors and valuation. The August figures were reported by Business Insider from three people with knowledge of the discussions and were a target, not a closing. The 43% is our arithmetic across two outlets and dates.
Business Engineer Framework
The Four Intelligence Moats
A Business Engineer framework on where intelligence accumulates in each AI paradigm and who can capture it.
Bloomberg reported on 22 October 2026 that Kevin Weil, who led OpenAI’s AI-for-science efforts, is launching a startup with $215 million, aimed at using AI to speed up a key step of drug development. In August, Business Insider reported that he was aiming to raise $150 million at a valuation of at least $750 million; by our arithmetic, $215 million is about 43% more than that target.
A note on sourcing. This piece is based on Bloomberg’s 22 October 2026 report, read first as a headline and summary on its X post and then in full as carried by Investing.com, and on Business Insider’s 11 August 2026 report, read in full via a syndicated copy; and our own earlier pieces. The 43% and 15% are our arithmetic. We cover the company at business level only. Nothing here is investment advice.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur (for example, How to Digitize a Family Business in Europe) and HackerNoon. Find him on LinkedIn and Substack. See how we source.
